Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,035actual
Sites
217
Countries
Australia, Belgium, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-25 | actual | When the study began enrolling |
| Primary completion | 2026-03-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-04 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Drug: capivasertib
- Drug: docetaxel
- Other: placebo
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS) in the overall population
measured up to approximately 46 months
Radiographic Progression-free Survival (rPFS) in the overall population
measured up to approximately 37 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed